Protocol

LDTAM: Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

Diseases

Leukemias / Lymphomas : For survivors of Hodgkin lymphoma

Description

Hodgkin lymphoma — formerly known as Hodgkin's disease — is a cancer of the lymphatic system, which is part of your immune system. Patients with Hodgkin lymphoma are typically treated with radiation, which has led to high survivorship. However, it has been found that Hodgkin lymphoma patients who received radiation to the chest area before age 30 have up to a 55 times higher risk of developing breast cancer than the average woman.

Tamoxifen has been successfully used in the treatment of breast cancer for about 40 years, and has been shown to help prevent new cancers from occurring. This study is going to test a two-year course of tamoxifen at the 5 mg daily dose in female Hodgkin lymphoma survivors to see if it will have the same effects as shown prior studies. If so, low-dose tamoxifen (5 mg per day) may be a good option for decreasing breast cancer risk in women who received chest radiation, with fewer side effects.


Objectives


Eligibility

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE  (1-866-278-5833).


Contact

Melissa Hudson, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN  38105  USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org


The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.